10578 Science Center Drive
San Diego, CA 92121
(858) 625 2424
5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560
Yvonne Greenstreet has over 20 years of global experience in the pharmaceutical industry, where she has a proven track record as a business leader and drug developer. She has been in senior roles in research and development, strategy, commercial development and portfolio management and has led product development and commercialization teams in a wide range of therapy areas of both small molecules and biologics. Over the course of her career, she has delivered 10 NDA/MAAs and numerous product launches.
Dr. Greenstreet was Senior Vice President and Head of Medicines Development at Pfizer, where she was on the global executive team for the $16 billion Specialty Business, with accountability for a portfolio that included the immuno-inflammation, vaccine, specialty neuroscience and rare disease areas. She led the approval of the JAK inhibitor Xeljanz, bringing to market the first of a new class of medicines for patients with rheumatoid arthritis. She was also instrumental in growing Pfizer's presence in rare diseases by driving strategy, delivering product approvals and securing in‐licensed opportunities.
Dr. Greenstreet was at GlaxoSmithKline (GSK) for 18 years as Senior Vice President and Chief of Strategy for Research and Development, serving on the corporate executive investment committee. She was responsible for enabling strategy development and execution to achieve GSK’s goal of delivering five to seven new medicines per year with an increase in return on investment from 11 to 14 percent by 2015. Dr. Greenstreet previously served in various positions of increasing responsibility at GSK, including Senior Vice President for Medicine Development, in which she led the creation of a new global unit which had responsibility for GSK's musculoskeletal, endocrine, gastrointestinal, ophthalmology and urological disease areas. She spearheaded GSK's entry into immuno‐inflammation and biologics with the in‐licensing of Benlysta for patients with lupus and Arzerra for patients with chronic lymphocytic leukemia. Prior to this role, she was Chief Medical Officer for GSK Europe, with responsibility for development and medical affairs of GSK’s entire pipeline and product portfolio in the region. She is highly regarded for her vision and ability in identifying emerging opportunities, her expertise in drug development and her success in building highly functioning organizations.
She currently serves on the Boards of Indivior PLC as well as Advanced Accelerator Applications S.A. She also serves on the Advisory Board of the Bill and Melinda Gates Foundation and has received widespread industry recognition, including being recognized by Fast Company as one of the 100 most creative people in business in the U.S. in 2013 and by Fierce Biotech as one of the top ten women in Biotechnology in 2012.
Dr. Greenstreet trained as a physician and earned her medical degree from Leeds University in the UK and her MBA from INSEAD, France.